Evidence map›Paper›PMID 37641719›Full record

ArticlePharmacogenomics and personalized medicine2023

Clinical Characteristics and Novel

Xiao Han, Qianjuan Zhang, Chengcheng Wang, Bingjuan Han

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xiao HanDepartment of Pediatrics, Jining First People's Hospital, Jining, Shandong, 272011, People's Republic of China.
Qianjuan ZhangDepartment of Children's Medical Rehabilitation Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250001, People's Republic of China.
Chengcheng WangDepartment of Pediatric Surgery, Jining First People's Hospital, Jining, Shandong, 272011, People's Republic of China.
Bingjuan HanDepartment of Children's Health Prevention, The Second Children & Women's Healthcare of Jinan City, Jinan, Shandong, 271100, People's Republic of China.ORCID 0000-0003-1021-4275
Jining First People's Hospital · CNJinan Maternity And Care Hospital · CNShandong Women’s University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Mowat-Wilson syndrome (MWS) is an autosomal dominant disease caused by a pathogenic variant of the Patients and Methods: The clinical characteristics of the patients were monitored and the treatment effect was followed up. DNA was extracted from peripheral blood and analyzed by sequencing. Whole exome sequencing was then performed. Results: Three novel Conclusion: Our study expanded the mutation spectrum of ZEB2 and enriched our understanding of the clinical features of MWS. It also shows that long-term standardized treatment is of great significance for the prognosis of patients.

Indexed as

gene mutationlong-term follow-upMowat-Wilson syndromerehabilitation treatmentZEB2

Identifiers

PMID37641719
PMCPMC10460601
OpenAlexW4386057087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.